MWG Caph Ltd Buys Shares of 1,008,116 Lyell Immunopharma, Inc. $LYEL

MWG Caph Ltd bought a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,008,116 shares of the company’s stock, valued at approximately $31,030,000. Lyell Immunopharma accounts for approximately 42.9% of MWG Caph Ltd’s investment portfolio, making the stock its 2nd largest holding. MWG Caph Ltd owned 4.75% of Lyell Immunopharma as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. GSK plc acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $46,560,000. ARCH Venture Management LLC raised its position in shares of Lyell Immunopharma by 51.5% in the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after acquiring an additional 938,438 shares during the period. Acadian Asset Management LLC raised its position in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares during the period. Vanguard Group Inc. raised its position in shares of Lyell Immunopharma by 76.0% in the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after acquiring an additional 336,378 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after acquiring an additional 154,327 shares during the period. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Trading Up 0.6%

NASDAQ:LYEL opened at $12.52 on Thursday. Lyell Immunopharma, Inc. has a 1-year low of $8.46 and a 1-year high of $45.00. The firm has a fifty day simple moving average of $18.66 and a 200 day simple moving average of $23.03. The stock has a market capitalization of $292.14 million, a PE ratio of -0.91 and a beta of -0.09.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The business had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -7.87 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LYEL has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a report on Monday. Finally, Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Lyell Immunopharma Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.